Clinical Trial Update: Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial compares apatinib plus irinotecan versus irinotecan alone as second-line treatment for advanced gastric cancer and adenocarcinoma of th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastric Junction
• Gastric Cancer

Drugs mentioned

• Apatinib (apatinib)
• Camptosar (irinotecan)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction | Phase 2 | Status: UNKNOWN